Aller au contenu principal
Accès ouvert déclaré 2025 article

Efficacy and Safety of the Bushen Quhan Zhiwang Decoction to Achieve Clinical Deep Remission in Rheumatoid Arthritis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by significant disability, with effective management of disease activity and pain constituting critical clinical objectives. The herbal formulation Bushen Quhan Zhiwang Decoction (BQZD) has demonstrated potential efficacy in symptom alleviation, suggesting a promising role in achieving sustained clinical remission in RA. The present study aims to systematically evaluate the efficacy and safety profile of BQZD for managing RA disease activity and pain relief. Patients and Methods: This randomized, double-blind, placebo-controlled, single-center clinical trial will enroll a total of 72 RA patients, randomly assigning them into either the intervention group (n=36) receiving BQZD or the placebo control group (n=36). Participants will consume either BQZD or placebo (100 mL, twice daily) over a 12-week intervention period. Clinical assessments are scheduled at enrollment and subsequently at 4-week intervals, continuing through the 16-week mark post-intervention initiation. The primary outcome measure is the Disease Activity Score for 28 joints (DAS28). Secondary outcome variables include visual analogue scale (VAS) pain scores, mechanical pain threshold (MPT), central sensitization inventory (CSI), patient-reported outcomes (PROs), Traditional Chinese medicine (TCM) symptom scores, and biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Safety endpoints will encompass monitoring of hematological parameters, urinalysis results, and adverse events. Discussion: This study seeks to generate robust clinical evidence verifying the therapeutic efficacy and safety of BQZD for alleviating pain and achieving deep remission in RA patients. These findings are anticipated to facilitate broader integration of traditional herbal medicine within clinical practice. Additionally, this research endeavors to provide clinically relevant insights into precision treatments for RA by integrating traditional Chinese medicine and Western medical approaches, and aims to lay foundational evidence for future investigations into underlying regulatory mechanisms and potential therapeutic targets of TCM.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Efficacy and Safety of the Bushen Quhan Zhiwang Decoction to Achieve Clinical Deep Remission in Rheumatoid Arthritis: Protocol for a Double-Blind, Randomized, Placebo-Controlled Trial
Date Crossref
01/08/2025
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Beijing University of Chinese Medicine Graduate School pays non établi dans la notice
    Université ou école supérieure
  • China-Japan Friendship Hospital Department of TCM Rheumatism pays non établi dans la notice
    Établissement de santé

Graduate School — Beijing University of Chinese Medicine et Department of TCM Rheumatism — China-Japan Friendship Hospital.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Rheumatoid Arthritis Research and TherapiesTraditional Chinese Medicine StudiesComplementary and Alternative Medicine Studies

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.